At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 27 enrolled
Drug / intervention
nedosirandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nedosiran in Pediatric Patients From Birth to 11Years of Age With Primary Hyperoxaluria and Relatively Intact Renal Function
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company·interventional·Posted Aug 11, 2021·Updated Apr 16, 2026
In Brief
A Phase 2 clinical trial evaluating nedosiran for Primary Hyperoxaluria and 3 related conditions. Completed, enrolled 27 participants across 13 sites in 11 countries.
Detailed Summary
The aim of this study is to evaluate nedosiran in participants 11 years of age and younger who have Primary Hyperoxaluria with relatively intact renal function.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Hyperoxaluria, Primary Hyperoxaluria Type 1, Primary Hyperoxaluria Type 2, Primary Hyperoxaluria Type 3
CountriesCanada, Germany, Italy, Japan, Lebanon, Poland, Spain, Turkey (Türkiye), United Arab Emirates, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartFeb 2022
Primary CompletionFeb 2025
TodayJul 2026
First PostedAug 11, 2021
Enrollment StartFeb 22, 2022
Primary CompletionFeb 5, 2025
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 4.9 years ago
Interventions
nedosirandrug
Monthly subcutaneous dosing throughout study period